Barrow begins ibogaine trial for brain injury recovery

Barrow Neurological Institute launches ibogaine trial

Barrow Neurological Institute has initiated a Phase 1/2 clinical trial to evaluate ibogaine's efficacy in treating neurological disorders, including traumatic brain injury (TBI). The study, supported by a $5 million grant from the Arizona Department of Health Services, is a collaboration between Barrow, the Barrow Neuro Analytics Center, and Arizona State University researchers.

Study details and objectives

The trial, led by principal investigator Anna Burke, MD, and co-investigators including Susan Criswell, MD, MSCI, aims to assess ibogaine's potential as a therapeutic agent for TBI. The double-blind, placebo-controlled study will enroll 40 participants with chronic TBI symptoms, with half receiving ibogaine and the other half a placebo. Standardized assessments will be used to evaluate changes in TBI symptoms and quality of life. The first participant is expected to be enrolled in 2027.

Research team and methodology

The multidisciplinary research team includes Barrow physician-scientists Michael T. Lawton, MD, Susan Herman, MD, and Chia-Ling Phuah, MD, MMSc, alongside collaborators from Arizona State University like Holly Lisanby, MD, and Candace Lewis, PhD. The trial will investigate physical changes associated with symptom improvements, contributing to a broader understanding of brain function and the potential of psychedelic medicine.

Why it matters

This trial is significant as it explores ibogaine, a psychoactive alkaloid, as a possible treatment for TBI, a condition with often incomplete recovery. The study's findings could pave the way for new therapeutic approaches for neurological disorders, enhancing quality of life for affected individuals. The research also represents a step forward in understanding brain circuitry and the impact of psychedelic substances on mental health.

Barrow's initiative highlights the growing interest in psychedelic medicine for neurological and psychological conditions.